This report on global Alzheimer’s therapeutics market studies various drugs used for the treatment of Alzheimer’s along with pipeline analysis of upcoming potential drugs. According to the Institute of Health Metrics and Evaluation, Alzheimer’s is one of the most common diseases that cause dementia, which leads to a loss of cognitive abilities, including reasoning, thinking, and remembering. Alzheimer’s is an irreversible, progressive brain disease that eventually destroys the ability to carry out the most basic tasks of daily living. While treatments to manage symptoms are available, Alzheimer’s has no cure. Thus, the drug pipeline of Alzheimer’s treatment market comprises potential drugs which are more target specific and posses innovative properties.
For the purpose of this study, the various drugs studied include memantine hydrochloride donepezil hydrochloride rivastigmine and galantamine hydrobromide.
The pipeline analysis for Alzheimer’s therapeutics market comprises projected market sales of Phase III drugs estimated till 2023. The phase III drugs included in the pipeline analysis are ENA713 (Novartis Pharmaceuticals), Flutemetamol (18F) (GE Healthcare), LY450139 (Eli Lilly and Company), Dimebon (Medivation, Inc. & Pfizer, Inc.), and Aripiprazole/ BMS-337039 (Otsuka Pharmaceutical, Inc.). The report also covers qualitative information associated with the drugs under phase II and I of the clinical trials.
The geographic segmentation of the global Alzheimer’s therapeutics market is performed for the regions North America, Europe, Asia Pacific and Rest of the World markets. The regions are also further sub-segmented on the basis of major countries.
According to Alzheimer’s Society, there are no drug treatments that can cure Alzheimer's disease or any other common type of dementia. However, medicines have been developed for Alzheimer's disease that can temporarily alleviate symptoms, or slow down their progression, in some cases. There are two types of drug classes used in treatment of Alzheimer’s disease, acetylcholinesterase (ACE) inhibitors and N-methyl-D-aspartate (NMDA) receptor antagonist.
According to press release published by BioArctic Neuroscience AB, the Alzheimer’s disease is age-related and the number of patients doubles every five years beyond age 65, meaning that 30% of 85-year-olds are suffering from the disease. Current estimates indicate 35.6 million people worldwide are affected and researchers estimate that this number could triple by 2050. According to medical practitioners, donepezil, rivastigmine or galantamine is offered as part of treatment for patients with mild-to-moderate Alzheimer's disease. However, use of memantine is for severe Alzheimer's disease and most of the medical practitioners recommend memantine for people with moderate Alzheimer's disease who cannot take the cholinesterase inhibitor drugs. The current market dynamics suggest that drugs currently available in the market are expected to lose their exclusivity during the forecast period. Hence, the current unmet needs represent a huge opportunity for pharmaceutical companies which are developing targeted novel therapies
According to Alzheimer’s Association, if no novel treatments are found to prevent, delay or stop the progression of Alzheimer’s disease, the number of people affected in the U.S. is expected to soar to 15 million by 2050 and the cost of care for Alzheimer’s patients could increase five-fold to $1.2 trillion a year. The drugs currently available in Alzheimer’s therapeutics market treat the cognitive symptoms of the disease such as memory loss, confusion and problems with thinking but do not address the underlying causes of the disease. However, ongoing research on Alzheimer’s treatment is focused on treatments that may restrain or slow down disease progression disease modifying agents. Other areas of research are concentrating at the role inflammation and insulin resistance developed in Alzheimer’s disease. According to market experts the major challenges in Alzheimer’s clinical trials are as follows:
North America was observed as the largest market for Alzheimer’s treatment in the base year 2021. According to Alzheimer’s Association, an estimated 5.2 million Americans of all ages have Alzheimer’s disease in 2021. This includes an estimated 5 million people aged 65 and older; approximately 200,000 individuals under age 65 who have younger-onset Alzheimer’s. The key factors driving North America Alzheimer’s therapeutics market are rise in prevalence of geriatric based diseases, aging population, high adoption of novel treatments and rising public awareness related to diagnosis of age-specific diseases. According to a study published by Institute for Health Metric and Evaluation, in 2013 Alzheimer’s and other dementias were responsible for about 3% of all deaths globally. In several countries, however, it caused more than 10% of all deaths in 2013: Finland (13%), Italy (11.4%), Iceland (10.9%), Switzerland (10.8%), Canada (10.8%), and the US (10.5%). Apart of higher-income countries middle-income countries in Southeast Asia, Eastern Europe, the Middle East, and elsewhere carry an increasingly large burden of Alzheimer’s deaths. In 2020, Indonesia, Ukraine, Mexico, Poland, Turkey, Vietnam, Thailand, Argentina, Pakistan, Bangladesh, and Iran had more than 10,000 deaths from Alzheimer’s. Thus, globally Alzheimer’s market is expected to grow significantly throughout the forecast period 2023 – 2030.
Historical & Forecast Period
This study report represents analysis of each segment from 2022 to 2032 considering 2023 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2024 to 2032.
The current report comprises of quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends and technological analysis, case studies, strategic conclusions and recommendations and other key market insights.
Research Methodology
The complete research study was conducted in three phases, namely: secondary research, primary research, and expert panel review. key data point that enables the estimation of Alzheimer’s Therapeutic market are as follows:
Market forecast was performed through proprietary software that analyzes various qualitative and quantitative factors. Growth rate and CAGR were estimated through intensive secondary and primary research. Data triangulation across various data points provides accuracy across various analyzed market segments in the report. Application of both top down and bottom-up approach for validation of market estimation assures logical, methodical and mathematical consistency of the quantitative data.
| ATTRIBUTE | DETAILS |
|---|---|
| Research Period | 2022-2032 |
| Base Year | 2023 |
| Forecast Period | 2024-2032 |
| Historical Year | 2022 |
| Unit | USD Million |
| Segmentation | |
Drug Type
| |
|
Region Segment (2022-2032; US$ Million)
|
Key questions answered in this report
